Prelude Therapeutics Inc Stock Price, News & Analysis

Prelude Therapeutics (NASDAQ: PRLD) announced an exclusive option agreement with Incyte on a previously undisclosed JAK2V617F mutant selective JH2 inhibitor, prioritized its KAT6A selective degrader program for ER+ breast cancer, and paused its SMARCA2 degrader clinical development.

The Incyte deal includes an upfront payment of $35M, a $25M equity investment, and up to $100M if the option is exercised; Prelude retains program ownership until exercise. As of Oct 31, 2025 Prelude had ~$52M cash and will receive $60M at close; cash runway is expected into 2027 or potentially into Q3 2028 if Incyte exercises the option. Prelude will report Q3 2025 results and hold a call on Nov 12, 2025.

Prelude Therapeutics (NASDAQ:PRLD) announced an exclusive option agreement with Incyte (NASDAQ:INCY) for Prelude’s mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms (MPNs).

Prelude will receive $60 million in capital at close ($35M upfront plus $25M strategic equity via 6.25M shares at $4.00), an option purchase price of $100 million, and up to $775 million in milestones plus royalties, for combined potential cash of $910 million excluding royalties. Prelude retains program rights if Incyte declines the option. Program data accepted for an oral ASH presentation Dec 6-9, 2025.

Prelude Therapeutics (Nasdaq: PRLD) announced publication of two abstracts accepted for oral presentation at the ASH 67th Annual Meeting, December 6-9, 2025 in Orlando.

The abstracts report preclinical data for two discovery programs: orally bioavailable JAK2V617F JH2 mutant-selective inhibitors showing mutant-specific inhibition, normalization of blood counts and spleen size in JAK2VF mouse models and selective reduction of JAK2VF progenitors; and mCALR-targeted DACs delivering a CDK9 degrader that selectively eliminates CALR-mutant MPN progenitors while sparing healthy CD34+ cells.

Prelude Therapeutics (Nasdaq: PRLD) announced that Katina Dorton, J.D., MBA was appointed to its Board of Directors effective October 17, 2025.

Ms. Dorton brings >30 years of healthcare and life‑sciences experience, including senior finance roles, investment banking, service as CFO at NodThera, and having raised $82 million in crossover funding while at Repare Therapeutics. She will succeed Mardi C. Dier, who is resigning from the board effective October 17, 2025, and Ms. Dorton will assume the role of Audit Committee chair.

Prelude Therapeutics (Nasdaq: PRLD) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company's oral SMARCA2 degrader PRT7732 is currently enrolling its seventh dosing cohort at 125mg, with preliminary data expected by year-end 2025. Prelude has completed Phase 1 study of PRT3789, its IV SMARCA2 degrader, but decided to pause its development to focus resources on PRT7732.

The company reported $77.3 million in cash and equivalents as of June 30, 2025, providing runway into Q2 2026. Q2 net loss was $31.2 million ($0.41 per share), improved from $34.7 million ($0.46 per share) in Q2 2024. The company remains on track to file an IND for its oral KAT6A degrader program in H1 2026.

Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, has announced its participation in two major healthcare conferences in June 2025. CEO Kris Vaddi, Ph.D., will participate in fireside chats at the Jefferies Global Healthcare Conference on June 5 at 3:10 p.m. ET and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 9:20 a.m. ET. Both presentations will be available via live webcast on the company's website and archived for 90 days. Prelude focuses on developing innovative medicines for cancer patients, with a pipeline including first-in-class SMARCA2 and KAT6A degraders, and is working on precision ADCs through partnerships.

Prelude Therapeutics (NASDAQ: PRLD) reported Q1 2025 financial results and pipeline updates. The company completed enrollment for PRT3789 monotherapy and docetaxel combination trials, with results expected in H2 2025. Their oral SMARCA2 degrader PRT7732 Phase 1 study is progressing rapidly. Financial highlights include $103.1M cash position extending runway into Q2 2026. Q1 2025 saw increased R&D expenses of $28.8M (vs $27.4M in Q1 2024) and decreased G&A expenses of $5.8M (vs $6.9M). Net loss was $32.1M ($0.42 per share). The company is advancing multiple programs including SMARCA2 degraders for SMARCA4-mutated cancers, KAT6A degraders, and precision ADCs, with several key milestones expected in 2025.

Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, announced its participation in the Citizens Life Sciences Conference in New York on May 7, 2025. The company's leadership team, including CEO Kris Vaddi, President and CMO Jane Huang, and CSO Peggy Scherle, will engage in a fireside chat at 11:00 a.m. ET. The event will be webcast live on Prelude's website and archived for 90 days. Prelude focuses on developing innovative medicines for cancer patients, with a pipeline including first-in-class SMARCA2 degraders and a CDK9 inhibitor. The company is also advancing Precision ADCs through partnerships.

Prelude Therapeutics (Nasdaq: PRLD) announced new preclinical data presentations at the 2025 AACR Annual Meeting for two key programs. The first presentation focuses on PRT3789, their first-in-class selective SMARCA2 degrader currently in Phase 1 and 2 clinical trials for advanced solid tumors with SMARCA4 loss.

The second presentation highlights their KAT6A degrader program, showing promising preclinical results in breast cancer and other solid tumors. Their selective KAT6A degraders demonstrated:

• Deep anti-cancer responses in KAT6A-amplified tumors
• Complete tumor regressions in breast and lung cancer xenografts
• Reduced hematologic toxicity compared to KAT6A/B inhibitors
• Effectiveness against endocrine therapy and CDK4/6i-resistant cells